Mounjaro vs Ozempic

Mounjaro (tirzepatide) and Ozempic (semaglutide) are both GLP-1 pathway agents reviewed for the treatment of type 2 diabetes. Mounjaro is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus, and for the treatment of symptomatic chronic heart failure with preserved ejection fraction (HFpEF) in adults with obesity. Ozempic is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus, and to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes mellitus and established cardiovascular disease.

Regulators reviewed Mounjaro's efficacy in improving glycemic control, with HbA1c effect sizes for tirzepatide versus placebo ranging from -1.33 to -1.56, and versus insulin degludec ranging from -0.6 to -0.91. Ozempic's review included its potency as a GLP-1 receptor agonist at 0.15 and its ED50 for lowering blood glucose (6 hours post dosing) in male diabetic db/db mice at 1.2.

It is crucial to understand that these drugs were studied in separate trials with different designs, populations, and timepoints. The endpoints, patient characteristics, and comparator arms varied between the studies. Therefore, the figures presented are not head-to-head comparisons, and neither drug is presented as superior to the other.